ECOPPIA
Ecoppia (TASE: ECPA), the world’s leader in robotic cleaning for photovoltaic solar panels, announced today the appointment of Mr. Amir Fishelov as a member of its board of directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005026/en/
Ecoppia Announces Appointment of Amir Fishelov, Co-Founder of SolarEdge Technologies to its Board of Directors (Photo: SolarEdge Technologies Ltd.)
Mr. Fishelov has more than 20 years of experience in the solar energy and technology fields and is the Co-Founder of SolarEdge Technologies (NASDAQ: SEDG), a global leader in smart energy technologies, which recently joined the S&P 500. During his time at SolarEdge, Mr. Fishelov served as the Chief Software Architect for 14 years, and in the last few years, he served as VP Strategy and Corporate Development.
During his military service, Amir spent 6 years leading research and development teams and directing large-scale, multidisciplinary R&D projects in software, analog design, communications, and signal processing at the Intelligence Corps Technology Unit – Unit 81.
Mr. Fishelov is also a decorated mind in the technology sector, having won the prestigious National Technological Innovation Award in both 2001 and 2003.
“We are pleased to welcome Amir to Ecoppia’s board,” says Ecoppia Co-Founder and Chairman, Eran Meller. “We believe Amir’s invaluable insights and vast expertise in the solar technology sector will steer initiatives that will drive growth and innovation at Ecoppia.”
About Ecoppia
For nearly a decade, with over 16GW of signed agreements, Ecoppia has been the pioneer and world leader in robotic cleaning solutions for PV. Offering a cloud-based platform and a suite of advanced solutions, Ecoppia’s fully autonomous robots cost-effectively maximize the performance of utility-scale PV sites all over the world. Remotely managed and controlled, the Ecoppia platform allows solar sites to maintain peak performance with minimal costs and human intervention.
Ecoppia in Numbers:
+ 3,900MW projects
+ 16,000MW signed agreements
+ 35 large scale projects
4 continents of operation
+ 8 billion panels cleaned
3 robotic platforms
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005026/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
10-Year Partnership Between ISN® and Yara International Enhances Ongoing Commitment to Contractor Safety14.5.2025 10:00:00 CEST | Press release
The global leader in crop nutrition continues to leverage ISNetworld® solutions to advance contractor compliance and safety practices ISN, the global leader in contractor and supplier information management services, celebrates 10 years of partnership with the European division of Yara International (Yara), a leading provider of crop nutrition and sustainable agricultural solutions. After a successful implementation in the Americas, Yara adopted ISNetworld across its European sites in 2015, expanding its use of the contractor management platform, streamlining processes, and improving operational efficiency. “Over the past decade, ISN has been instrumental to Yara’s contractor management processes in Norway and the Netherlands," said Steinar Bjelland, Procurement Manager at Yara. "Leveraging ISNetworld tools and services such as RAVS 360™ and acknowledgment form tracking, along with ISN’s multilingual support, has helped Yara optimise compliance, improve communication, and effectively a
Ares Management Opens Milan Office14.5.2025 10:00:00 CEST | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the opening of a new office in Milan, the firm’s latest office in Europe. The office will enhance Ares’ access to the Italian market, and its ability to raise and invest capital across its strategies, particularly within its European Direct Lending business, as well as the Wealth Management and European Real Estate platforms. This latest opening underscores Ares’ commitment to a highly localized approach to investing in Europe, which the firm entered in 2007 through the opening of a London office, followed by Paris, Frankfurt and Stockholm in 2009 and, most recently, Amsterdam and Madrid in 2019. Across its investment strategies, including European Direct Lending and European Real Estate, Ares has deployed over €1.6 billion to support Italian businesses and assets, as of March 31, 2025, and Ares expects to accelerate this activity in the coming years. Tyrone Cooney, Partn
Intelsat, Cubic³ Complete Vehicle Satellite Connectivity Test, Advancing Ubiquitous Connectivity Vision14.5.2025 09:00:00 CEST | Press release
Groundbreaking Memorandum of Understanding brings seamless, global connectivity closer to reality for connected cars, agriculture, and heavy machinery vehicles Intelsat and Cubic³ have successfully completed a critical vehicle satellite connectivity test, marking a significant milestone in their joint mission to create a seamless connectivity service for all types of vehicles. The test demonstrated successful integration between Intelsat satellites and Cubic³’s software platform, showcasing how terrestrial and non-terrestrial networks can seamlessly link to deliver always-on connectivity regardless of location. “Our Memorandum of Understanding and successful test brings us closer to our vision of truly ubiquitous connectivity,” said Bruno Fromont, Intelsat Chief Technology Officer. “By combining Intelsat’s satellite expertise with Cubic³’s innovative connectivity platform, we’re creating solutions that will keep vehicles connected anywhere in the world, enabling critical functions from
Norli Liv & Pension Modernizes Investment Operations with Clearwater Analytics14.5.2025 09:00:00 CEST | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Danish pension provider, Norli Liv & Pension, part of the Norli group, has partnered with Clearwater to modernize its investment accounting, reporting and compliance operations. Clearwater will provide Norli with a single, consolidated view of all in-house and outsourced chief investment officer (OCIO) managed holdings across its public and private asset classes—enhancing investment transparency and empowering better, faster decision-making. The platform will also support regulatory compliance through automated workflows and robust, audit-ready reporting. By moving to Clearwater’s single instance, multi-tenant platform, Norli Liv & Pension will eliminate multiple legacy platforms, reduce manual work and accelerate its monthly close. The platform’s “single pane of glass” view will provide users across departments with unified access to accurate, timely data and a
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)14.5.2025 08:14:00 CEST | Press release
Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment options Phase II data show potential of efimosfermin to reverse liver fibrosis, demonstrated in metabolic dysfunction-associated steatohepatitis (a form of SLD) Unique properties offer potential for efimosfermin to be a new standard-of-care Significantly expands GSK’s hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease, offering multiple development options and potential first launch in 2029 GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progress
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom